Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
Stimulus - Learn Tools to Crush It in Your Medical Career - 61 - Outpatient COVID-19 Therapy with Salim Rezaie, MD

61 - Outpatient COVID-19 Therapy with Salim Rezaie, MD

10/14/21 • 30 min

Stimulus - Learn Tools to Crush It in Your Medical Career

The treatment of non-hospitalized patients suffering from COVID-19 is a hot topic and constantly changing. Today we have a conversation with Salim Rezaie, MD whose dive into this literature couldn’t be much deeper. We discuss which subgroup of patients might benefit from monoclonal antibodies, why the jury is still out on the benefit of ivermectin, the role of inhaled budesonide, and outpatient anticoagulation which hasn’t been studied, but hopefully will be someday.

Guest Bio: Salim Rezaie completed his medical school training at Texas A&M Health Science Center and continued his medical education with a combined Emergency Medicine/Internal Medicine residency at East Carolina University. He currently works as a community emergency physician at Greater San Antonio Emergency Physicians (GSEP) where he is the director of clinical education. Salim is the creator and founder of REBEL EM and REBEL Cast, a free, critical appraisal blog and podcast that tries to cut down knowledge translation gaps of research to bedside clinical practice. Hear more from Salim on Stimulus #16 Accumulation of Marginal Gains.

We Discuss:

  • The fact that the best treatment of COVID is prevention through vaccination [2:30];
  • The value and purported benefit of monoclonal antibodies [03:21];
  • Whether a rapid antibody test would help predict seronegativity [06:30];
  • Specifically which monoclonal antibodies are being used in Salim’s shop [07:40];
  • The irony of people demanding monoclonal antibodies, but refusing vaccination because they don’t know what's in it [08:50];
  • Why you can’t trust everything you read about COVID therapy in a news headline [12:40];
  • One of the largest ivermectin studies which was based on falsified data, yet continues to influence the results of meta-analyses [15:30];
  • Inhaled budesonide for COVID-19 symptom control [22:00];
  • The slippery slope of outpatient anticoagulation [23:39];
  • The things Salim might do if he had symptomatic COVID-19 and was well enough to be managed as an outpatient [27:25];
  • And more.

For complete shownotes: https://roborman.com/stimulus/61-outpatient-covid-19-therapy-with-salim-rezaie-md/

Interested in one-on-one coaching? https://roborman.com/about-us/coaching/

Our landing page: https://roborman.com/

This podcast streams free on iTunes, Spotify, and Stitcher.

Follow Rob: Twitter, Facebook, and Youtube.

plus icon
bookmark

The treatment of non-hospitalized patients suffering from COVID-19 is a hot topic and constantly changing. Today we have a conversation with Salim Rezaie, MD whose dive into this literature couldn’t be much deeper. We discuss which subgroup of patients might benefit from monoclonal antibodies, why the jury is still out on the benefit of ivermectin, the role of inhaled budesonide, and outpatient anticoagulation which hasn’t been studied, but hopefully will be someday.

Guest Bio: Salim Rezaie completed his medical school training at Texas A&M Health Science Center and continued his medical education with a combined Emergency Medicine/Internal Medicine residency at East Carolina University. He currently works as a community emergency physician at Greater San Antonio Emergency Physicians (GSEP) where he is the director of clinical education. Salim is the creator and founder of REBEL EM and REBEL Cast, a free, critical appraisal blog and podcast that tries to cut down knowledge translation gaps of research to bedside clinical practice. Hear more from Salim on Stimulus #16 Accumulation of Marginal Gains.

We Discuss:

  • The fact that the best treatment of COVID is prevention through vaccination [2:30];
  • The value and purported benefit of monoclonal antibodies [03:21];
  • Whether a rapid antibody test would help predict seronegativity [06:30];
  • Specifically which monoclonal antibodies are being used in Salim’s shop [07:40];
  • The irony of people demanding monoclonal antibodies, but refusing vaccination because they don’t know what's in it [08:50];
  • Why you can’t trust everything you read about COVID therapy in a news headline [12:40];
  • One of the largest ivermectin studies which was based on falsified data, yet continues to influence the results of meta-analyses [15:30];
  • Inhaled budesonide for COVID-19 symptom control [22:00];
  • The slippery slope of outpatient anticoagulation [23:39];
  • The things Salim might do if he had symptomatic COVID-19 and was well enough to be managed as an outpatient [27:25];
  • And more.

For complete shownotes: https://roborman.com/stimulus/61-outpatient-covid-19-therapy-with-salim-rezaie-md/

Interested in one-on-one coaching? https://roborman.com/about-us/coaching/

Our landing page: https://roborman.com/

This podcast streams free on iTunes, Spotify, and Stitcher.

Follow Rob: Twitter, Facebook, and Youtube.

Previous Episode

undefined - Deeper Stimulus Book Club 1 Announcement

Deeper Stimulus Book Club 1 Announcement

Scott Weingart and I will be hosting a book club.

When: Nov 14th 20:00 EST

Where: Via Zoom

Who: Anyone who will actually read the book and wants to participate. We are limiting this first one, so please don't sign up unless you are genuinely interested. We will be releasing a recording for those folks that want a passive experience.

Nonviolent Communication: A Language of Life: Life-Changing Tools for Healthy Relationships

How: Sign-Up Here. If we are full, put your name on the waiting list

Next Episode

undefined - 62.  Primum Non Nocere | How 8 doctors practice 'first do no harm'

62. Primum Non Nocere | How 8 doctors practice 'first do no harm'

In this episode we hear from eight leading physician educators about a core principle of patient care: primum non nocere. We learn that limiting harm can translate into doing what’s medically right, putting the patient’s welfare first, judicious use of IV fluids, reducing opioid prescribing, making a habit of pausing when depleted, acknowledging the end of life, and allowing a natural death.

Awake + Aware | Our 2025 Live Event

⭐ Join us at Awake and Aware 2025, a game-changing 3-day workshop from May 5-7 in Bend, Oregon. Learn how to stay cool when the pressure’s on and lock in the mindset you need to flourish. Space is limited.

🖱️ Website: Awakeandawarebend.com

🎓 P.S. Yes, this is a CME event!

The Flameproof Course

The hidden anti-burnout curriculum we all should have learned in training. Cohort 3 begins Sept 10, 2024. Get the deets

For full show notes of this episode and all sorts of other goodies, visit our podcast website

Episode Comments

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/stimulus-learn-tools-to-crush-it-in-your-medical-career-36815/61-outpatient-covid-19-therapy-with-salim-rezaie-md-18222325"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to 61 - outpatient covid-19 therapy with salim rezaie, md on goodpods" style="width: 225px" /> </a>

Copy